NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Marea Therapeutics

Marea Therapeutics

Private
South San Francisco, CaliforniaHealthcare & Life Scienceshttps://www.mareatx.com/

Last Round

Series B

Jun 18, 2024

Total Funding Raised

$190M

Company Overview

Marea Therapeutics is a biotechnology company that develops first-in-class therapies for cardioendocrine diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

biotechnologymonoclonal antibodycardiovascular diseaseclinical trialsbiotechdrug developmentacromegalyatherosclerotic cardiovascular diseaseASCVDclinical-stage biotechtherapeutic candidateendocrine diseasedrug pipelinebiopharma

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Marea Therapeutics Comparables

Compare Marea Therapeutics with similar companies based on industry and business-model similarity.

Marea Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Roche Holding
76%
Amgen
73%
Eli Lilly and Company
73%

Marea Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BJun 18, 2024

Key People

Founding team and executive leadership

Ethan Weiss

Chief Scientific Officer, Co-Founder

Founding Team

Josh Lehrer

Chief Executive Officer

Executive Team

Ian Clements

Chief Financial Officer

Executive Team

Marea Therapeutics Investors

Notable investors and investment history

Marea Therapeutics investors
InvestorRounds
Surveyor CapitalSeries B
Omega FundsSeries B
ForbionSeries B
Perceptive AdvisorsSeries B
CitadelSeries B
venBioSeries B
Alpha Wave GlobalSeries B

Market signals

Structured signals derived from secondary market and firmographic data.

  • Mar 4, 2026

    Third asset in research discovery, with DC nomination expected next year.

  • Mar 4, 2026

    Second asset, MAR002, enters Phase 1 for acromegaly.

Marea Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Marea Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Marea Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersSouth San Francisco, California
Employee Range42
Year Founded2022
Last FundingJun 18, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.